Driving groundbreaking research. Improving lives.

Helping people with an MPN live a better quality of life as we work toward answers to prevention, progression and a cure for polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms.

MPNRF By the Numbers

$ 0 M

What is Primary Myelofibrosis (MF)?

Primary Myelofibrosis (MF)

PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF

What is Essential Thrombocythemia (ET)?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is Polycythemia Vera (PV)

Polycythemia Vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

Recent News

  • MPN News to Expect at ASH 2023

    MPN NEWS | November 29, 2023

    Each year at the Annual Meeting of The American Society of Hematology (ASH), there are more MPN research and clinical trial reports. This year, some unique highlights include 16 topics we find notable, along with many others with a potential connection to MPNs.  Artificial intelligence (AI) to differentiate between essential thrombocythemia and prefibrotic primary myelofibrosis. … Read More »MPN News to Expect at ASH 2023


    Investigation of IL-1RAP in Myeloproliferative Neoplasms: Potential Novel Anti-leukemic Therapy

    MPN NEWS | November 29, 2023

    Thrive Award Spotlight : Idoroenyi Amanam, MD Using our own immune system to treat cancers has become a reality for many solid and blood cancers. “It’s an ideal therapy, as it’s our own specialized system that helps treat abnormal cells,” according to Idoroenyi Amanam, MD, of City of Hope. For MPNs, there is a need… Read More »Investigation of IL-1RAP in Myeloproliferative Neoplasms: Potential Novel Anti-leukemic Therapy


    2024-2026 Patient Impact Council Announced

    MPN NEWS | October 26, 2023

    An MPNRF Patient Impact Council recently launched to actively advocate for the patient voice and perspective in all aspects of our work to promote research advances and therapies with meaningful patient benefits.    Created with very clear objectives and activities, the council includes individuals representing diversity in MPN experiences, diagnosis, skills, community connections, geographic locations, and… Read More »2024-2026 Patient Impact Council Announced

  • Ready to do more?

    Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

    Stay Connected

    With an investment today, you can accelerate research for better outcomes.

    By supporting MPN Research Foundation, you’re also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.


    Want to learn more about MPNs? Be the first to know about what’s going on in the PV, ET, and MF community.
    Get our monthly update,
    “Under the Microscope”